CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistant Acinetobacter baumannii in ICU patients based on mechanical ventilation, carbapenem exposure, and hospitalization duration

CRAB-RSS:基于机械通气、碳青霉烯类药物暴露和住院时间,开发和验证用于ICU患者碳青霉烯耐药鲍曼不动杆菌感染的单中心风险分层模型

阅读:1

Abstract

PURPOSE: This study aimed to develop and validate the Carbapenem-Resistant Acinetobacter baumannii Risk Scoring System (CRAB-RSS), a novel predictive model designed to assess the risk of carbapenem-resistant A. baumannii (CRAB) infection in intensive care unit (ICU) patients. METHODS: A retrospective cohort analysis was performed on 412 patients (315 with CRAB and 97 with carbapenem-susceptible A.baumannii [CSAB]) from 2020 to 2024. Three independent risk factors were identified: mechanical ventilation (adjusted odds ratio [aOR] = 3.2, 95% confidence interval [CI]: 1.8-5.6), prior carbapenem exposure (≥48 hours; aOR = 1.89, 95% CI: 1.32-2.71), and hospitalization duration exceeding 14 days (aOR = 1.67, 95% CI: 1.25-2.23). RESULTS: The model demonstrated robust discriminative ability, with an area under the receiver operating characteristic curve (AUROC) of 0.887 in the derivation cohort and 0.918 in the validation cohort, along with satisfactory calibration (Brier score: 0.094 versus 0.088). Its performance was significantly superior to that of the Sequential Organ Failure Assessment (SOFA) score (ΔAUROC = +0.21). CONCLUSIONS: CRAB-RSS is a quantitative risk stratification tool derived from a single-center cohort for CRAB infections in intensive care unit patients, demonstrating superior performance to SOFA in local validation. External multicenter validation is warranted before broad clinical implementation. Its innovative features include: (1) a fixed-weighting design (e.g., assigning a baseline score of 2 points for mechanical ventilation), and (2) reliance on only three readily obtainable clinical variables to complete the assessment. Decision curve analysis revealed that the application of CRAB-RSS could reduce unnecessary carbapenem use by 28%-42% across probability thresholds of 10%-30%, with a maximum reduction of 38% achieved at the 20% threshold.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。